| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200461 | Ophthalmology | 2016 | 11 Pages |
Abstract
Regardless of dose (0.5 or 2.0 mg), monthly ranibizumab injections promote improvement and reduce progression of RNP compared with PRN injections. The addition of scatter photocoagulation to ranibizumab PRN may reduce progression of RNP in patients with BRVO, but a statistically significant reduction was not seen in patients with CRVO.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Tahreem A. MD, Saleema MD, Gulnar MD, MPH, Adrienne W. MD, Ingrid MD, Adam S. MD, PhD, Sharon MD, Ian MD, David MD, Lingmin MD, Syed Mahmood MD, Christopher J. MD, Catherine MD, Akrit MD, PhD, Marguerite O. Linz, Raafay MD, Peter A. MD,